TABLE 2.
Individual participant characteristics and anti-retroviral therapy regimens at the time of leukapheresis a
| Participant ID |
Sex at birth | Age at first leukapheresis | CD4 count | HIV status at treatment | ART at leukapheresis |
|---|---|---|---|---|---|
| A | Male | 66 | 610 | Chronic | DRV/ABC/3TC |
| B | Male | 25 | 706 | Acute | EVG/c/TDF/FTC |
| C | Female | 45 | 1,168 | Acute | EVG/c/TDF/FTC |
| D | Female | 45 | 1,788 | Chronic | RPV/TDF/FTC |
| E | Female | 55 | 704 | Chronic | RPV/TDF/FTC |
| F | Male | 41 | 737 | Chronic | RLT/TDF |
| G | Female | 34 | 948 | Chronic | EVG/c/TDF/FTC |
| H | Female | 61 | 934 | Chronic | ABC/DTG/3TC |
| I | Male | 50 | 732 | Chronic | 3TC/DDI/FPV/NVP/RTVb |
| J | Female | 38 | 1,238 | Chronic | RPV/TDF/FTC |
| K | Male | 37 | 922 | Chronic | RPV/TDF/FTC |
| L | Female | 48 | 580 | Chronic | NVP/TDF |
| M | Female | 44 | 1,203 | Chronic | EFV/FTC/TDF |
| N | Female | 54 | 484 | Chronic | EVG/c/FTC/TAF |
| O | Male | 30 | 382 | Chronic | DTG/ABC/3TC |
| P | Male | 52 | 1,277 | Chronic | EFV/FTC/TDF |
| Q | Male | 28 | 530 | Acute | RPV/TAF/FTC |
| R | Male | 49 | 707 | Chronic | EFV/FTC/TDF |
| S | Female | 38 | 844 | Chronic | ATZ/RTV/FTC/TDF |
| T | Male | 50 | 664 | Chronic | ABC/DTG/3TC |
| U | Male | 57 | 1,045 | Chronic | EVG/c/TDF/FTC |
| V | Female | 56 | 593 | Chronic | EVG/c/TDF/FTC |
| W | Female | 53 | 1,121 | Chronic | DTG/ABC/3TC |
| X | Male | 28 | 574 | Chronic | DRV/RTV/TDF/FTC |
| Y | Female | 50 | 636 | Chronic | ABC/3TC/DRV/RTV |
| Z | Female | 37 | 873 | Chronic | RTV/TDF/FTC/ATV |
| AA | Female | 31 | 1,224 | Chronic | FTC/TDF/DTG |
| BB | Female | 55 | 576 | Chronic | RPV/TDF/FTC |
| CC | Female | 55 | 893 | Chronic | FTC/RPV/TDF |
| DD | Male | 25 | 729 | Acute | ABC/DTG/3TC |
a
DRV—darunavir, ABC—abacavir, 3TC—lamivudine, EVG—elvitegravir, c—cobicistat, TDF—tenofovir, TDF DF—tenofovir disoproxil fumarate, FTC—emtricitabine, DTG—dolutegravir, RAL—raltegravir, NVP—nevirapine, EFV—efavirenz, RTV—ritonavir, and ATV—atazanavir.